<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673335</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0104/0701 - ONCO03</org_study_id>
    <secondary_id>ONCO-03/0701</secondary_id>
    <secondary_id>EU-20806</secondary_id>
    <secondary_id>NOVARTIS-FNCLCC-ONCO 03/0701</secondary_id>
    <secondary_id>2007-000687-24</secondary_id>
    <nct_id>NCT00673335</nct_id>
  </id_info>
  <brief_title>Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation</brief_title>
  <acronym>LIBER</acronym>
  <official_title>Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Letrozole may prevent breast cancer in postmenopausal women with a BRCA1 or BRCA2
      mutation.

      PURPOSE: This randomized phase III trial is studying letrozole to see how well it works
      compared with a placebo in preventing breast cancer in postmenopausal women with a BRCA1 or
      BRCA2 mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the reduction of the incidence of invasive breast cancer in postmenopausal
           women with the BRCA1/BRCA2 mutation treated with letrozole.

      Secondary

        -  Determine the reduction of the incidence of in situ breast cancer in these women.

        -  Determine the recurrence rate of local or metastatic disease in women who have had
           breast cancer.

        -  Determine the incidence of non-breast cancer, especially ovarian, colon, or endometrial
           cancer.

        -  Assess the tolerance of this drug in terms of lipid, cardiovascular, and bone effects.

        -  Determine the quality of life of women treated with this drug.

        -  Identify serological markers that allow early diagnosis of hereditary predisposition for
           breast cancer.

        -  Conduct pharmacogenetic analysis.

        -  Identify biomarkers or genes involved in the occurrence of cardiovascular and
           rheumatologic metabolic aromatase inhibitors.

        -  Study the phenotypic characteristics of cancers that occur during treatment with
           letrozole, in particular hormonal markers (estrogen and progesterone receptor) and
           expression profiles of resistance to therapy.

      OUTLINE: This is a multicenter study. Patients are stratified according to nature of mutation
      (BRCA1 vs BRCA2), oophorectomy in premenopausal state (yes vs no), and prior breast cancer
      (yes vs no). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral letrozole once daily.

        -  Arm II: Patients receive oral placebo once daily. Treatment in both arms continues for 5
           years in the absence of unacceptable toxicity or development of cancer or recurrent
           disease.

      Blood samples are collected periodically for pharmacogenetic studies and analysis of
      biomarkers or genes associated with hereditary predisposition for breast cancer, toxicities,
      and resistance to therapy.

      After completion of study treatment, patients are followed for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without contralateral or unilateral invasive breast cancer at 5 years (prior breast cancer)</measure>
    <time_frame>2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival without invasive breast cancer at 5 years</measure>
    <time_frame>2017</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Invasive cancer-free survival at 10 years</measure>
    <time_frame>2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer in situ-free survival at 5 and 10 years</measure>
    <time_frame>2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free (local or metastatic disease) survival in patients with history of breast cancer at 5 and 10 years</measure>
    <time_frame>2017 and 2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second cancer-free survival at 5 and 10 years</measure>
    <time_frame>2017 and 2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event- free (local relapse or metastatic, contralateral, or second cancer) survival at 5 and 10 years</measure>
    <time_frame>2017 and 2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 5 and 10 years</measure>
    <time_frame>2017 and 2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to CTCAE version 3.0</measure>
    <time_frame>2017 and 2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid tolerance or cardiovascular or bone event</measure>
    <time_frame>2017 and 2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life according to MRS and SF36 questionnaires</measure>
    <time_frame>2017 and 2022</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>brca1 Mutation Carrier</condition>
  <condition>brca2 Mutation Carrier</condition>
  <condition>Breast Cancer</condition>
  <condition>Hereditary Breast/Ovarian Cancer (brca1, brca2)</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole, 1 tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comparator, 1 tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Must meet the following criteria:

               -  With or without invasive unilateral breast cancer more than 5 years ago, with no
                  recurrence

                    -  No evidence of breast cancer by mammography or MRI within the past year

               -  Carrier of the BRCA1/BRCA2 deleterious mutation (nonsense mutation or stop)

               -  Refused preventive mastectomy

          -  No prior bilateral breast cancer

          -  No prior bilateral mastectomy

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Menopausal status as indicated by 1 of the following criteria:

               -  Age &gt; 60 years

               -  Bilateral oophorectomy

               -  Age ≤ 60 years with no hysterectomy or amenorrhea within the past 12 months

               -  Age ≤ 60 years with prior hysterectomy or FSH &gt; 20 IU/L

          -  Eastern Cooperative Oncology Group (ECOG) or WHO performance status 0-1

          -  absolute neutrophil count (ANC) &gt; 2,000/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Hemoglobin &gt; 10 g/dL

          -  Bilirubin normal

          -  ALT and AST &lt; 2.5 times upper limit of normal

          -  Creatinine clearance ≥ 60 mL/min

          -  Adequate cardiovascular function (e.g., no history of myocardial infarction, angina
             pectoris, or heart failure)

          -  No osteoporosis by bone density scan (DEXA) within the past 2 years or prior
             osteoporotic fracture (femur, lumbar spine T score &gt; -2 DS)

        Exclusion criteria:

          -  Invasive cancer diagnosed in the past 5 years, except for basal cell or squamous cell
             skin cancer or carcinoma in situ of the cervix

          -  Prior cerebrovascular accident

          -  Prior cardiac ischemia

          -  Hypersensitivity to letrozole or its excipients, especially titanium oxide

          -  Renal or hepatocellular insufficiency, cholestasis, or cytolysis

          -  Geographical, social, or psychological reasons that preclude medical monitoring in
             this study

          -  Deprived of liberty or guardianship

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 3 months since prior and no concurrent hormone replacement therapy (e.g.,
             thyroid-stimulating hormone)

          -  No prior hormonal therapy in the past year

          -  No concurrent participation in another therapeutic study with an experimental drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Pujol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Arnaud de Villeneuve</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>02</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General de Niort</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Michel</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Etienne - Hopital Nord</name>
      <address>
        <city>Sainte-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP, Tennevet I, Chabbert-Buffet N, This P, Baudry K, Lemonnier J, Roca L, Mijonnet S, Gesta P, Chiesa J, Dreyfus H, Vennin P, Delnatte C, Bignon YJ, Lortholary A, Prieur F, Gladieff L, Lesur A, Clough KB, Nogues C, Martin AL; French Federation of Cancer Centres (FNCLCC). Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam Cancer. 2012 Mar;11(1):77-84. doi: 10.1007/s10689-011-9484-4.</citation>
    <PMID>22076253</PMID>
  </reference>
  <results_reference>
    <citation>Pujol P, Mijonnet S, Karen S, et al.: Breast cancer prevention by letrozole in post menopausal BRCA1/2 mutations carriers: The Onco-03/LIBER trial. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-1048, 2009.</citation>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>hereditary breast/ovarian cancer (BRCA1, BRCA2)</keyword>
  <keyword>BRCA1 mutation carrier</keyword>
  <keyword>BRCA2 mutation carrier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

